Assessment of 54 biomarkers for biopsy-detectable prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 10, 2007, Pages 1966-1972

  Parekh, Dipen J ^a,f   Ankerst, Donna Pauler ^a   Baillargeon, Jacques ^a   Higgins, Betsy ^a   Platz, Elizabeth A ^a   Troyer, Dean ^c   Hernandez, Javier ^d   Leach, Robin J ^a,b   Lokshin, Anna ^e   Thompson, Ian M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUROPSIN; PLASMINOGEN ACTIVATOR INHIBITOR; RESISTIN; STROMELYSIN; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; TUMOR BIOPSY;

ADIPOKINES; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CLUSTER ANALYSIS; COHORT STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METALLOPROTEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TEXAS;

EID: 35448972867     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0302     Document Type: Article

References (23)

1. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer [review]. Int J Oncol 2006;28:737-45.
2. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-5.
3. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-15.
4. Uehara H, Troncoso P, Johnston D, et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005;64:409.
5. Cardillo MR, Di Silverio F, Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006;26:973-82.
6. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005;33:44-50.
7. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002;191:208-16.
8. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655-63.
9. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20:833-41.
10. Lekas A, Lazaris AC, Deliveliotis C, et al. The expression of hypoxia-inducible factor-1α (HIF-1α) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 2006;26:2989-93.
11. Gann PH, Klein KG, Chatterton RT, et al. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, clinically normal prostates. Prostate 1999;40:248-55.
12. Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001;61:42537.
13. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006;29:305-14.
14. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
15. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
16. Szklo M, Nieto J, Miller M. Epidemiology: beyond the basics. Gaithersburg (MD): Aspen Publishers, Inc.; 2000.
17. Gorelik E, Landsittel D, Marrangoni A, et al. Multiplexed immunobeadbased cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
20. Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 2006;61:401-8.
21. Haese A, Graefen M, Huland H, Lilja H. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Curr Urol Rep 2004;5:231-40.
22. Borgono CA, Kishi T, Scorilas A, et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 2006;12:1487-93.
23. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006;68:1152-5.